Jonathon E. Himes

This paper develops a new mouse model of CIC::DUX4 sarcoma and identifies Minnelide as a selective inhibitor effective in preclinical models.

The paper compares radiation response in autochthonous and transplant sarcomas in mice with and without adaptive immunity, finding higher cure rates in transplant tumors with immune function.

This study shows that combining radiotherapy with CpG, a TLR9 agonist, enhances tumor response in a mouse sarcoma model by boosting CD8 T cell activity.